Subject Index

ACTH, gestational cocaine and, 336
Addiction, dopamine-independent mechanisms and, 228
S-Adenosylmethionine, blood and liver, 191
Adrenal, gestational cocaine and, 336
Adrenergic system, heroin plus cocaine influence on, 208
Aging, noradrenergic neurons and, 166
Alcoholism, brain damage and, 50
Amphetamine
  dopamine D_3 receptor and, 27
  fenfluramine compared to, 138
Amygdala, dopamine D_3 receptor and, 27
Animal behavioral models, proof of concept in, 275
Animal studies, potential medications for treating cocaine addiction and, 77
Antioxidant enzymes, METH-induce changes in, 92
Anxiety, ibogaine and, 241
AP-1 transcription factor complex, cocaine and, 1
Appetite suppressant, fenfluramine as, 138
Astrogliosis, METH and, 108

Blood *S*-adenosylmethionine, METH and, 191
Brain stem, ibogaine and, 266

c-fos, acute administration of cocaine and, 7
c-Fos, 23
Ca^{2+} levels, cocaine and, 236
Calcium channel blockers, cocaine abuse and, 202
Calpain, tissue destruction of spinal cord injury and, 132
cAMP response element, animal brain and, 23
Cardiovascular response, ibogaine and, 271
Caudate nucleus
  ibogaine and, 266
  isradipine pretreatment and, 206
Cellular toxicity, ibogaine and, 284
[^{3}H]CGP 39653, ibogaine and, 247
Clinical trial, pilot efficacy, cocaine addiction and, 76
Clonidine, noradrenergic neurons and, 167
Cocaine
  AP-1 transcription factor complex and, 1
  chemical structure of, 229
  dopamine D_3 receptor and, 27
  dopamine uptake and release and, in striatum and nucleus accumbens, 346
  heroin plus, 208
  isradipine and, 201
  PKC action of, 227
  postnatal pituitary-adrenal axis activity and, 336
  pregnancy outcome and, 324
  self-administration of, ibogaine and, 216
  serotonergic system and, 7
  stress endurance and, 336
  uterine position and, 314
Cocaine addiction, research issues related to development of medications for treatment of, 75
Cocaine-conditioned motoric activity, 61
Cognitive function, cocaine in nonhuman primates and, 178
Cognitive impairments, NMDA and, 308
Color and position discrimination
  cocaine in nonhuman primates and, 179
  d-FEN vs MDMA and, 185
Conditioned cue preference paradigm, dopamine D_3 receptor and, 31
Conditioned place preference, 61
Conditioned position responding task, cocaine in nonhuman primates and, 179
Copper/zinc-superoxide dismutase transgenic mice, METH and, 92
Cortex, astrocytes from, 110
Corticosterone
  fenfluramine challenge and, 141
  gestational cocaine and, 336

DAMGO, ibogaine and, 281
Developmental periods, methamphetamine and, 310
Dexfenfluramine, MDMA vs, 183
Dialysates, DA levels in, 167
5,7-Dihydroxytryptamine, gene expression and, 8

Subject Index

ACTH, gestational cocaine and, 336
Addiction, dopamine-independent mechanisms and, 228
S-Adenosylmethionine, blood and liver, 191
Adrenal, gestational cocaine and, 336
Adrenergic system, heroin plus cocaine influence on, 208
Aging, noradrenergic neurons and, 166
Alcoholism, brain damage and, 50
Amphetamine
  dopamine D_3 receptor and, 27
  fenfluramine compared to, 138
Amygdala, dopamine D_3 receptor and, 27
Animal behavioral models, proof of concept in, 275
Animal studies, potential medications for treating cocaine addiction and, 77
Antioxidant enzymes, METH-induce changes in, 92
Anxiety, ibogaine and, 241
AP-1 transcription factor complex, cocaine and, 1
Appetite suppressant, fenfluramine as, 138
Astrogliosis, METH and, 108

Blood *S*-adenosylmethionine, METH and, 191
Brain stem, ibogaine and, 266

c-fos, acute administration of cocaine and, 7
c-Fos, 23
Ca^{2+} levels, cocaine and, 236
Calcium channel blockers, cocaine abuse and, 202
Calpain, tissue destruction of spinal cord injury and, 132
cAMP response element, animal brain and, 23
Cardiovascular response, ibogaine and, 271
Caudate nucleus
  ibogaine and, 266
  isradipine pretreatment and, 206
Cellular toxicity, ibogaine and, 284
[^{3}H]CGP 39653, ibogaine and, 247
Clinical trial, pilot efficacy, cocaine addiction and, 76
Clonidine, noradrenergic neurons and, 167
Cocaine
  AP-1 transcription factor complex and, 1
  chemical structure of, 229
  dopamine D_3 receptor and, 27
  dopamine uptake and release and, in striatum and nucleus accumbens, 346
  heroin plus, 208
  isradipine and, 201
  PKC action of, 227
  postnatal pituitary-adrenal axis activity and, 336
  pregnancy outcome and, 324
  self-administration of, ibogaine and, 216
  serotonergic system and, 7
  stress endurance and, 336
  uterine position and, 314
Cocaine addiction, research issues related to development of medications for treatment of, 75
Cocaine-conditioned motoric activity, 61
Cognitive function, cocaine in nonhuman primates and, 178
Cognitive impairments, NMDA and, 308
Color and position discrimination
  cocaine in nonhuman primates and, 179
  d-FEN vs MDMA and, 185
Conditioned cue preference paradigm, dopamine D_3 receptor and, 31
Conditioned place preference, 61
Conditioned position responding task, cocaine in nonhuman primates and, 179
Copper/zinc-superoxide dismutase transgenic mice, METH and, 92
Cortex, astrocytes from, 110
Corticosterone
  fenfluramine challenge and, 141
  gestational cocaine and, 336

DAMGO, ibogaine and, 281
Developmental periods, methamphetamine and, 310
Dexfenfluramine, MDMA vs, 183
Dialysates, DA levels in, 167
5,7-Dihydroxytryptamine, gene expression and, 8

DOPAC
d-FEN vs MDMA and, 186
7-nitroindazole and, 123
time-course of ibogaine effects on, 254
uterine position and, 314
Dopamine
cocaine binding and, 7
d-FEN vs MDMA and, 186
ibogaine vs, 231
uterine position and, 314
withdrawal from chronic cocaine in rats and, 60
Dopamine-β-hydroxylase, heroin plus cocaine abuse and, 209
Dopamine D_3 receptor, function of, 27
Dopamine depletion, blood and liver *S*-adenosylmethionine and, 191
Dopamine receptors, binding of, 296
Dopamine release
cocaine in striatum and nucleus accumbens and, 348
prenatal cocaine exposure and, 295
Dopamine systems, age-dependent effects of cocaine on brain function of rhesus monkeys and, 178
Dopamine transporter
binding of, 295
ibogaine binding to, 253
methamphetamine and, 105
Dopamine uptake
cocaine in striatum and nucleus accumbens and, 347
prenatal cocaine exposure and, 294
Dopaminergic neurotoxicity, 7-nitroindazole and, 122
Drug addiction, ibogaine as treatment for, 252
DSP-4, noradrenergic neurons and, 167
[^{3}H]DTG, ibogaine and, 247
Dual deficit model of cocaine addiction, 60

Efficacy measures, potential cocaine treatment medication, 83
egr-1, acute administration of cocaine and, 7
Electroencephalogram, ibogaine and, 266
Estrogen, striatal dopaminergic neurotoxicity and, 153
Estrogen receptor, neuroprotective actions of estrogen and, 163
Extracellular monoamine levels, isradipine pretreatment and, 204

Fenfluramine
central serotonin function and, 138
cocaine addiction and, 60
Fetal uterine position, 320
Fluoxetine, *egr-1* expression and, 9
Fos-related antigens (Fras)
AP-1 transcription factor and, 2
chronic, 3
14-3-3 protein, 21
Free radicals, calpain activation mechanism in SCI and, 134
Frontal cortex
Cu/Zn-SOD activity in, 94
ibogaine and, 266
Fura-2, Ca^{2+} levels and, 237

$GABA_A$ receptors
human brain and, 51
pathogenesis and, 51
subunit isoforms of, 51
Gas chromotography/mass spectrometry, cocaine exposure and, 315
Gender, MPTP and, 158
Gene expression, regulation of, 2
Genetic approach, unraveling function and, 27
GFAP
activated, reactive astrocytes and, 109
estrogen replacement and, 159
onset of reactive gliosis and, 40
GFAP mRNA, MAP kinase cascade and, 41
Gliosis
astrocyte expression of vimentin and GFAP and, 115
MPTP model of neurotoxicity and, 40
Glutamine synthase, astrocytes and, 109
Glutathione peroxidase, activity of, in Cu/Zn-SOD-Tg mice, 95
[^{3}H]Glycine, ibogaine and, 247

Hallucinations, ibogaine and, 223
Harmaline, chemical structure of, 229
Heroin, cocaine plus, 208
5-HIAA
d-FEN vs MDMA and, 186
fenfluramine challenge and, 141
7-nitroindazole and, 124
Homogenates, DA levels in, 167
5-HT_3 receptor subclass, effects of cocaine and, 16

HVA
d-FEN vs MDMA and, 186
7-nitroindazole and, 123
time-course of ibogaine effects on, 254
uterine position and, 314

Ibogaine
chemical structure of, 229
dopamine-independent mechanisms and, 228
electroencephalogram and, 265
mechanisms of antiadictive actions of, 214
medication development of, 274
MK-801 vs, 252
monoamine concentrations and, 265
NMDA receptor complex and, 245
sigma binding sites and, 245
Ibogaine metabolism, 223
Immediate early genes, acute administration of cocaine and, 7
Immunohistochemical changes, transcription regulatory factor, 22
In situ hybridization, riboprobes for *c-fos* and *egr-1* and, 8
Isradipine, cocaine-induced locomotor response and, 203
Issues, research, development of medications for treatment of cocaine addiction and, 75

JunD, chronic Fras and, 4

[^{3}H]Kainate, ibogaine and, 247
Kappa receptor, ibogaine and, 217

Lactate dehydrogenase, astrocyte viability and, 110
Lateral hypothalamus, postmortem tissue levels of 5-HT and 5-HIAA in, 146
Learning
cocaine in nonhuman primates and, 179
d-FEN vs MDMA and, 185
prenatal cocaine exposure and, 325
Lipid peroxidation, METH-induce changes in, 92
Liver *S*-adenosylmethionine, METH and, 191
Locus coeruleus, noradrenergic neurons and, 166
LSD, ibogaine and, 222

Macaca mulatta, age-dependent effects of cocaine on brain function of, 179
MAP kinase, MPTP and, 40
MDMA, d-FEN vs, 183
Medications, development of, for treatment of cocaine addiction, 75
Mesencephalon, astrocytes from, 110
Methamphetamine
blood and liver *S*-adenosylmethionine and, 191
Cu/Zn-SOD-Tg mice and, 92
developmental exposure to, 310
dopamine transporters and, 103
7-nitroindazole and, 122
noradrenergic neurons and, 167
selective regional response of cultured astrocytes to, 108
transcription regulatory factors in striatum and, 22
tryptophan hydroxylase and, 103
Mice
dopamine D_3 receptor mutant, 28
noradrenergic neuron loss in, 9.4
Microdialysis, *in vivo*, 60, 216
Microwave irradiation, *in vivo* steady-state phosphorylation of MAP kinase and, 46
[^{3}H]MK-801, ibogaine and, 246, 253, 281
Morphine, self-administration of, ibogaine and, 216
Morris water task, NMDA and, 304
Motivation
cocaine in nonhuman primates and, 179
d-FEN vs MDMA and, 185
Motor activity, calcium channel blockers and, 202
MPTP
astrocytes and, 109
estrogen and, 155
MAP kinase cascade and, 40
Myelin, spinal cord injury and, 133

Neurobiology, cocaine's actions and, 240
Neuroendocrine challenge, functional integrity of 5-HT neurons in FEN-treated rats and, 139
Neuroprotection, estrogen and, 162
Neurotoxicity
ibogaine and, 218
gender and, 154
Nicotine, self-administration of, ibogaine and, 216

Nicotine gum clinical efficacy trials, summary of, 84
7-Nitroindazole, METH-induced neurotoxicity and, 122
NMDA, cognitive deficit in juvenile rats produced by, 303
NMDA ion channels, ibogaine binding to, 253
NMDA receptor complex, ibogaine and, 217, 245, 281
Noradrenergic neurons, striatal dopamine depletion and, 166
Noribogaine
  identification of primary metabolite as, 277
  mechanisms of antiadictive actions of, 214
NOS inhibitor, 7-nitroindazole as, 122
Nucleus accumbens
  cocaine and dopamine uptake and release in, 346
  dopamine D_3 receptor and, 27
  dopaminergic neurons in, 7
  isradipine pretreatment and, 205
  postnatal dopaminergic systems in, 293
Neuronal loss, localized, 50

Olfactory tubercle, dopamine D_3 receptor and, 27
Operant test battery, cocaine in nonhuman primates and, 179
Opioid receptors, 215
OVX mice, E_2-supplemented mice vs, 161
Oxidative stress, GSH-Px and, 99

Parkinson's disease, noradrenergic neurons and, 166
PC12 cells, incubation of, with cocaine, 234
[^{3}H]Pentazocine, ibogaine and, 247
Pharmacotherapy, ibogaine as, 283
Phencyclidine, ibogaine and, 246
Phentermine, cocaine addiction and, 60
Phosphorylated cAMP response element, 23
Phosphorylation, MAP kinase and, 46
Postnatal rats, NMDA and, 304
Power spectra, ibogaine and, 267
Pregnancy outcome, cocaine and, 324
Prenatal cocaine exposure
  postnatal dopaminergic systems and, 293
  pregnancy outcome and, 325
Progesterone, uterine position and, 321
Progressive ratio task, cocaine in nonhuman primates and, 179
Prolactin, fenfluramine challenge and, 141
Protein kinase C, ibogaine and, 232

Rat
  developing, methamphetamine and, 310
  noradrenergic neuron loss in, 169
Reactive oxygen species, cellular changes caused by DA and, 103
Receptor affinity, potential medications for treating cocaine addiction and, 77
Receptor pharmacology, alcoholics and, 54
Receptor protein expression, alcoholics and, 53
Reward
  dopamine and, 230
  ibogaine and, 230
Rhesus monkeys, age-dependent effects of cocaine on brain function of, 178
RNA expression, alcoholics and, 53

Safety, ibogaine and, 284
Self-administration
  cocaine, 68, 215
  morphine sulfate, 215
  nicotine, 215
Serotonergic neurotoxicity, 7-nitroindazole and, 122
Serotonergic system, heroin plus cocaine influence on, 208
Serotonin
  chemical structure of, 229
  cocaine binding sites and, 7
  d-FEN vs MDMA and, 186
  ibogaine binding to, 253
  fenfluramine's selective stimulation of, 138
  withdrawal from chronic cocaine in rats and, 60
Serotonin behavioral syndrome, fenfluramine challenge and, 141
Serotonin depletion, fenfluramine challenge and, 141
Serotonin function, fenfluramine impairment of, 139
Serotonin neurotoxin, fenfluramine as, 139
Serotonin release, fenfluramine known to stimulate, 138
Serotonin uptake site, ibogaine and, 222
Sexual development, prenatal cocaine exposure and, 326
Short-term memory and attention task, d-FEN vs MDMA and, 184

Sigma binding sites, ibogaine and, 245
Sigma-2 receptors, ibogaine and, 218
Signal transduction, PKC and, 239
[^{3}H]Spermidine, ibogaine and, 247
Spinal cord injury, calpain and, 131
Stress, gestational cocaine and, 336
Striatum
  astrocytes from, 110
  blood and liver *S*-adenosylmethionine and, 191
  cocaine and dopamine uptake and release in, 346
  concentrations of MPP^+ in, 156
  Cu/Zn-SOD activity in, 94
  dopamine transpoter activity in, 105
  mouse, 43
  noradrenergic neurons and, 167
  postnatal dopaminergic systems in, 293
  transcription regulatory factors in, 21
Substance use disorders, ibogaine and, 252
Synaptic plasticity, NMDA and, 303

[^{3}H]TCP, ibogaine and, 246
Teratogenic findings, uterine position and, 315
Therapeutic agents, calpain-specific inhibitors and, 135
Time estimation task, d-FEN vs MDMA and, 184
Transcription regulatory factors, immunohistochemical changes of, 21
Tremor analysis, whole body, 285
Tryptophan hydroxylase, methamphetamine and, 104

Vacuoles, GFAP expression and, 110
Ventral pallidum, dopamine D_3 receptor and, 27
Ventromedial hypothalamus, postmortem tissue levels of 5-HT and 5-HIAA in, 146
Vimentin, activated, reactive astrocytes and, 109

Western blot, differential expression of PKC isoforms and, 238

Yohimbine, noradrenergic neurons and, 167

Index of Contributors

Abreu, M. A. V., 208–213
Alessandri, M. G., 166–177
Ali, S. F., x, 122–130, 153–165, 183–190, 191–200, 201–207, 227–244, 245–251, 252–264, 265–273
Ansah, T. A., 201–207
Aunis, D., 7–20
Ayestas, M. A., 138–152

Banik, N. L., 131–137
Bassi, L., 166–177
Baumann, M. H., 59–74, 138–152, 252–264
Beaudoin, M. A., 265–273
Binienda, Z., 265–273
Buck, B. E., 274–292

Cadet, J. L., 92–102
Carvey, P. M., 314–323
Chakrabarti, A., 227–244
Choi, S.-J., 293–302, 324–335, 336–345
Clay, L. H., 346–355
Cooney, C. A., 191–200
Corsini, G. U., 166–177

Davis, B., 131–137
Dodd, P. R., 50–58

Elmer, G. I., 59–74

Fleckenstein, A. E., 103–107
Fogle, C. M., 265–273
Fontes Ribeiro, C. A., 208–213
Fornai, F., 166–177
Frederick, D. L., 183–190

Gibb, J. W., 103–107
Gillam, M. P., 178–182, 183–190
Glick, S. D., 214–226
Gobaille, S., 7–20
Gomes-da-Silva, J., 310–313
Gossett, J., 183–190

Hanson, G. R., 103–107
Hayashi, S., 21–26
Hearn, W. L., 274–292
Hogan, E. L., 131–137
Hope, B. T., 1–6
Humblot, N., 7–20

Ichikawa, T., 21–26
Itzhak, Y., 122–130, 245–251

Jayanthi, S., 92–102
Johnson, J. R., 265–273

Klein, M., 75–91
Kokoshka, J. M., 103–107
Kolta, M. G., 293–302, 346–355
Kovera, C. A., 274–292
Kumanishi, T., 21–26

Ladenheim, B., 92–102
Lau, J. W. S., 108–121
Laws, S. C., 153–165
Lewohl, J. M., 50–58
Ling, Z., 314–323
Lipton, J. W., 314–323

Macedo, T. R. A., 208–213
Maisonneuve, I. M., 214–226
Martin, P. M., 40–49
Mash, D. C., 274–292
Mass, M. J., 40–49
Matzelle, D., 131–137
Mazzio, E., 293–302, 324–335, 336–345, 346–355
Metzger, R. R., 103–107
Miller, D. B., 153–165
Mills, K., 201–207
Morgadinho, T., 208–213
Morris, P., 178–182
Muratake, T., 21–26

Norenberg, M. D., 274–292

Onaivi, E. S., 227–244
O'Callaghan, J. P., 40–49, 153–165

Paule, M. G., 178–182, 183–190
Poirier, L. A., 191–200
Prapurna, D. R., 265–273

Ray, S., 131–137
Rea, W., 59–74
Reams, R. R., 336–345
Robie, H. S., 314–323
Rothman, R. B., 59–74, 138–152, 252–264
Rudy, J. W., 303–309

Sanchez-Ramos, J., 274–292
Scalori, V., 166–177
Shapshak, P., 274–292
Shields, D. C., 131–137
Shippenberg, T. S., 59–74
Shockley, D. C., 201–207
Silva, M. C., 310–313
Sircar, R., 303–309
Slikker, W., Jr., 183–190, 265–273
Soliman, K. F. A., 293–302, 324–335, 336–345, 346–355
Stadlin, A., 108–121
Szeto, Y. K., 108–121

Takahashi, Y., 21–26
Tavares, M. A., 310–313
Thiriet, N., 7–20
Thorn, B. T., 265–273
Torracca, M. T., 166–177
Toyooka, K., 21–26

Weese-Mayer, D. E., 314–323
Wilford, G., 131–137
Wise, C. K., 191–200

Xu, M., 27–39

Zwiller, J., 7–20